Ghabanchi 2009.

Methods	Study design: RCT Conducted in Iran Number of centres: 1 Recruitment period: unclear Funding source: Shiraz University of Medical Sciences
Participants	Inclusion criteria: not specified Exclusion criteria: not specified Group A: randomised 9; analysed 9 Group B: randomised 11; analysed 11
Interventions	Group A: prednisolone 5 mg mucoadhesive tablet, twice daily for 2 weeks Group B: triamcinolone acetonide 0.1% paste, 3 times daily for 2 weeks
Outcomes	Clinical score (5‐grade score), adverse effects Quote: "Every variable (pain, atrophy, ulceration and interference in daily life) was evaluated independently by the same experienced clinician at 2–6 follow ups (the first one 48 hours after the beginning of treatment)."
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: insufficient information to permit judgement.
Allocation concealment (selection bias)	Unclear risk	Comment: insufficient information to permit judgement.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not feasible.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not feasible.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: no missing data. All randomised participants included in result analysis.
Selective reporting (reporting bias)	High risk	Comment: ≥ 1 outcomes of interest were reported incompletely (standard deviations were missing) so they could not be entered in a meta‐analysis. Data on adverse effects were not reported clearly (quote: "many patients dislike the bitter taste of topical prednisolone mucoadhesive tablet").
Other bias	Low risk	No other sources of bias identified.